{
    "organizations": [],
    "uuid": "70dae70a02c1f0c8e4725967e7962261032a3bbf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-regenxbio-enters-strategic-partner/brief-regenxbio-enters-strategic-partnership-with-fujifilm-diosynth-biotechnologies-idUSFWN1PI18C",
    "ord_in_thread": 0,
    "title": "BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - Regenxbio Inc:\n* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES\n* REGENXBIO-UNDER TERMS REGENXBIO GAINS GUARANTEED CAPACITY FOR SUPPLY OF NAV AAV DRUG SUBSTANCE MANUFACTURED UNDER CGMP AT LARGE SCALE FOR THREE YEARS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-24T05:49:00.000+02:00",
    "crawled": "2018-01-24T15:38:43.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "regenxbio",
        "inc",
        "regenxbio",
        "enhances",
        "gene",
        "therapy",
        "manufacturing",
        "capability",
        "entering",
        "strategic",
        "partnership",
        "fujifilm",
        "diosynth",
        "biotechnology",
        "term",
        "regenxbio",
        "gain",
        "guaranteed",
        "capacity",
        "supply",
        "nav",
        "aav",
        "drug",
        "substance",
        "manufactured",
        "cgmp",
        "large",
        "scale",
        "three",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}